Cytogenetic response to dasatinib
| . | Follow-up for 6 mo, no. (%) . | Follow-up for 8 mo, no. (%) . | ||||
|---|---|---|---|---|---|---|
| Total . | Imatinib-resistant . | Imatinib-intolerant . | Total . | Imatinib-resistant . | Imatinib-intolerant . | |
| All patients | 107 (100) | 99 (100) | 8 (100) | 107 (100) | 99 (100) | 8 (100) |
| CCyR | 23 (22) | 23 (23) | 0 (0) | 26 (24) | 25 (25) | 1 (13) |
| PCyR | 10 (9) | 9 (9) | 1 (13) | 9 (8) | 9 (9) | 0 (0) |
| MCyR (CCyR and PCyR) | 33 (31) | 32 (32) | 1 (13) | 35 (33) | 34 (34) | 1 (13) |
| Minor CyR | 6 (6) | 6 (6) | 0 (0) | 6 (6) | 6 (6) | 0 (0) |
| Minimal CyR | 19 (18) | 16 (16) | 3 (38) | 20 (19) | 17 (17) | 3 (38) |
| No CyR | 37 (35) | 34 (34) | 3 (38) | 33 (31) | 30 (30) | 3 (38) |
| Unable to determine | 12 (11) | 11 (11) | 1 (13) | 13 (12) | 12 (12) | 1 (13) |
| . | Follow-up for 6 mo, no. (%) . | Follow-up for 8 mo, no. (%) . | ||||
|---|---|---|---|---|---|---|
| Total . | Imatinib-resistant . | Imatinib-intolerant . | Total . | Imatinib-resistant . | Imatinib-intolerant . | |
| All patients | 107 (100) | 99 (100) | 8 (100) | 107 (100) | 99 (100) | 8 (100) |
| CCyR | 23 (22) | 23 (23) | 0 (0) | 26 (24) | 25 (25) | 1 (13) |
| PCyR | 10 (9) | 9 (9) | 1 (13) | 9 (8) | 9 (9) | 0 (0) |
| MCyR (CCyR and PCyR) | 33 (31) | 32 (32) | 1 (13) | 35 (33) | 34 (34) | 1 (13) |
| Minor CyR | 6 (6) | 6 (6) | 0 (0) | 6 (6) | 6 (6) | 0 (0) |
| Minimal CyR | 19 (18) | 16 (16) | 3 (38) | 20 (19) | 17 (17) | 3 (38) |
| No CyR | 37 (35) | 34 (34) | 3 (38) | 33 (31) | 30 (30) | 3 (38) |
| Unable to determine | 12 (11) | 11 (11) | 1 (13) | 13 (12) | 12 (12) | 1 (13) |
Data are provided as number (%) of patients. Cytogenetic response was defined by the prevalence of Ph+ metaphases: CCyR, 0% Ph+; PCyR, 1% to 35% Ph+; minor CyR, greater than 35% to 65% Ph+; minimal CyR, greater than 65% to 95% Ph+; no response, greater than 95% Ph+.
CyR indicates cytogenetic response; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; PCyR, partial cytogenetic response.